AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15198752
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy intervention program (6 sessions between weeks 2 and 6 after birth)
Trial: 3288460
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pirenzepine daily intravenously for a mean of 3.9 days
Trial: 3288460
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ranitidine daily intravenously for a mean of 3.9 days
Trial: 3288460
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ranitidine
Trial: 30683061
Drug: Garlic extract
RxNorm normalized name: Garlic Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic extract (400 mg twice a day for 8 weeks)
Trial: 26563012
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (1 mg/kg), administered once daily for 2 days and tapered down, completed on day 10
Trial: 26563012
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (1 mg/kg)
Trial: 23308174
Drug: Pegfilgrastim (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (100 ug/kg single dose)
Trial: 23308174
Drug: Filgrastim (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim (5 ug/kg/day for 9 doses)
Trial: 16440209
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen (CEO) 0.625 mg daily
Trial: 10962221
Drug: Adjunctive imipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive imipramine added to fluphenazine decanoate and benztropine
Trial: 10962221
Drug: Adjunctive antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive antidepressant medication
Trial: 1613811
Drug: GM-1 ganglioside
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-1 ganglioside treatment
Trial: 6488704
Drug: Low tar
RxNorm normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tar cigarette with nicotine yield of 0.55 mg (LN)
Trial: 6488704
Drug: Low tar
RxNorm normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tar cigarette with nicotine yield of 0.90 mg (MN)
Trial: 24824051
Drug: Pre-treatment snack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment snack with education messages
Trial: 20956409
Drug: Prenatal corticosteroid
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal corticosteroid therapy
Trial: 15329600
Drug: Dexmedetomidine (0.09,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.09, 0.24, 0.54, and 1.23 ng/ml)
Trial: 15329600
Drug: Alfentanil (13.4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (13.4, 33.8, 67.8, and 126.1 ng/ml)
Trial: 7982345
Drug: Newer pharmacologic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer pharmacologic agents
Trial: 29603130
Drug: Inspiratory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory Muscle Training (IMT) - home-based program using a flow-resistive inspiratory loading device, training twice a day at high intensity for 2 weeks or longer until surgery
Trial: 24899130
Drug: Composite graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite graft (bioactive porous Poly dl-lactide-co-glycolide scaffolds with antibiotic gentamicin and crosslinked gelatin)
Trial: 22237870
Drug: Partially hydrolyzed
RxNorm normalized name: Human Skin Proteins, Partially Hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolyzed whey formula with 10(6) CFU Bb12/g (PRO)
Trial: 18423901
Drug: Unobserved dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unobserved dosing
Trial: 18423901
Drug: Observed dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observed dosing
Trial: 15746667
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (50 microg initially followed by 100 microg in each subsequent dose)
Trial: 15746667
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (25 microg in each dose)
Trial: 12933402
Drug: Phenylephrine 2
RxNorm normalized name: phenylephrine 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 2 micro g/kg
Trial: 11103227
Drug: Tofu (290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofu (290 g daily)
Trial: 11103227
Drug: Meat (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat (150 g lean meat daily)
Trial: 8624148
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% tretinoin cream
Trial: 6700383
Drug: Thrice weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice weekly intra‐muscular injections of 7.5 to 10 megaunits of interferon/m2
Trial: 6700383
Drug: Daily injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily injections of interferon
Trial: 30394493
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy, mean duration 10.1±3.9 days
Trial: 22929964
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (250 or 500 ml of a milk whey based green tea containing soft drink)
Trial: 17563741
Drug: Intensive timed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive timed induction therapy
Trial: 15649852
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 50 microg bid
Trial: 15649852
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 100 microg bid
Trial: 15649852
Drug: Theophylline (orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (orally dose titrated slow‐release)
Trial: 9951784
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and calcitriol supplements
Trial: 2696020
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements
Trial: 3297230
Drug: Oxycone-papaverine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycone-papaverine (5 mg + 50 mg)
Trial: 31689141
Drug: Telemedicine intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine intervention (TM-group) with follow-up every 3 months and monthly telemedicine support.
Trial: 19058068
Drug: Ovarian cancer
RxNorm normalized name: Autologous, DNP-Modified Ovarian Cancer Vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian cancer psychoeducational intervention (OCPI) - 4 sequential, structured, in-person educational sessions
Trial: 20562702
Drug: TAK-242 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-242 1.2 mg/kg/day
Trial: 20562702
Drug: TAK-242 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-242 2.4 mg/kg/day
Trial: 15684116
Drug: Amoxicillin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (60 mg/kg daily for 10 days)
Trial: 15684116
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and Placebo
Trial: 11925355
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg of thyroxine daily
Trial: 7895394
Drug: Supervised training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised training twice a week for 3 months
Trial: 3075410
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of tripamide
Trial: 3075410
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of hydrochlorothiazide
Trial: 11307810
Drug: Argatroban (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (higher doses)
Trial: 11307810
Drug: Co-therapy (argatroban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-therapy (argatroban and warfarin)
Trial: 23075570
Drug: Early discharge
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early discharge from hospital after 3 days inpatient treatment with home visits by generic community nurses
Trial: 19858233
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of eight biomarkers (von Willebrand factor antigen, surfactant protein D, tumor necrosis factor receptor‐1, interleukin [IL]‐6, IL‐8, intercellular adhesion molecule‐1, protein C, plasminogen activator inhibitor‐1) and clinical predictors (APACHE III, organ failures, age, underlying cause, alveolar‐arterial oxygen gradient, plateau pressure)
Trial: 17885562
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 mg daily
Trial: 15699722
Drug: Meniett device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meniett device treatment (pressure pulses at 6 Hz for 0.6 seconds, oscillating between 0.4 and 1.2 kPa)
Trial: 15699722
Drug: Meniett device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meniett device treatment
Trial: 12084604
Drug: First treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First treatment (both methods pooled)
Trial: 12084604
Drug: Second treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second treatment (both methods pooled)
Trial: 7638950
Drug: Dihydroergotamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine (1 mg) with metoclopramide (10 mg)
Trial: 7638950
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg) with metoclopramide (10 mg)
Trial: 2495710
Drug: Flecainide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (1 mg/kg bolus over 10 minutes followed by 1.5 mg/kg/hr for 1 hour and then 0.25 mg/kg/hr for 24 hours)
Trial: 2495710
Drug: Digoxin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (3 bolus doses: 0.5 mg followed after 6 and 12 hours by 0.25 mg)
Trial: 972015
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy started within two months of oophorectomy
Trial: 972015
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy started after three years post-oophorectomy
Trial: 972015
Drug: Delayed estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed estrogen replacement therapy started after six years post-oophorectomy
Trial: 30653528
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two high construal level approaches
Trial: 28705454
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg ATLG
Trial: 28705454
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg ATLG
Trial: 25226850
Drug: QAX576 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAX576 (6 mg/kg)
Trial: 24429201
Drug: Proton-pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton-pump inhibitor or H2 blocker
Trial: 24429201
Drug: No anti-acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-acid treatment
Trial: 21729174
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (0.1 mL injected intradermally)
Trial: 21729174
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (0.1 mL injected subdermally)
Trial: 21729174
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (0.1 mL injected subcutaneously)
Trial: 21729174
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of circulating insulin detemir‐specific antibodies by RIA before and after 3 months
Trial: 21729174
Drug: Control (Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Saline injection)
Trial: 19555936
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (60 mL) followed by 2 L of PEG-ELS (Prep 3)
Trial: 19555936
Drug: Magnesium hydroxide
RxNorm normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium hydroxide (15 g) followed by 2 L of PEG-ELS (Prep 2)
Trial: 19555936
Drug: Conventional volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional volume (4 L) of PEG-ELS (Prep 1)
Trial: 17145603
Drug: Oral chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chlorambucil
Trial: 17145603
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy and autologous or allogeneic stem cell transplantation
Trial: 17145603
Drug: Schedules including
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedules including non-cross-reactive agents, such as alemtuzumab
Trial: 12932242
Drug: 1% coal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% coal tar preparation
Trial: 20713833
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream
Trial: 2071723
Drug: Amitriptyline therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline therapy (25, 50, or 75 mg/day)
Trial: 6318346
Drug: Bi‐Profenid tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi‐Profenid tablets (300 mg in 2 daily oral doses)
Trial: 6318346
Drug: Profenid capsules
RxNorm normalized name: ibuprofen Oral Capsule [Wal-Profen]
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Profenid capsules (300 mg in 3 daily oral doses)
Trial: 6318346
Drug: Profenid capsules
RxNorm normalized name: ibuprofen Oral Capsule [Wal-Profen]
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Profenid capsules
Trial: 6318346
Drug: Bi‐Profenid tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi‐Profenid tablets
Trial: 30904207
Drug: Almonds (AS:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almonds (AS: 56 g/day)
Trial: 27759780
Drug: Intravenous Cephazolin
RxNorm normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Cephazolin (2 g) during anesthetic induction
Trial: 24815851
Drug: 20 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg/kg of palifermin
Trial: 24815851
Drug: 40 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg/kg of palifermin
Trial: 24815851
Drug: 60 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 μg/kg of palifermin
Trial: 17552379
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) intervention plus treatment as usual (mask fitting and information)
Trial: 10193216
Drug: Intravenous anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anaesthesia using propofol
Trial: 3294189
Drug: gallopamil (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil (150 mg/day)
Trial: 3294189
Drug: nifedipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (30 mg/day)
Trial: 8201643
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ofloxacin
Trial: 2879872
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg norfloxacin
Trial: 8201643
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg ciprofloxacin
Trial: 2953380
Drug: Ioxaglate (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate (320 mg I/ml, osmolality 0.58 ml/kg)
Trial: 5440568
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 mug aerosol inhalation)
Trial: 5440568
Drug: Isoprenaline (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (1,000 mug aerosol inhalation)
Trial: 30845818
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus samidorphan (5 mg)
Trial: 30845818
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus samidorphan (10 mg)
Trial: 30845818
Drug: Olanzapine plus
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine plus samidorphan (20 mg)
Trial: 28803820
Drug: INSIGHT (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INSIGHT (1 unit/day increase in insulin dosage)
Trial: 28803820
Drug: EDITION (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDITION (dose adjusted by investigator at least once weekly)
Trial: 25867912
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg once daily (OD)
Trial: 25867912
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg twice daily (BD)
Trial: 9743848
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction (Sevoflurane)
Trial: 3265624
Drug: New trimethoprim/sulfamethoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New trimethoprim/sulfamethoxazole preparation (Kepinol forte, 160 mg of trimethoprim/800 mg of sulfamethoxazole)
Trial: 3265624
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (customary in trade and registered according to the AMG 1976)
Trial: 27222510
Drug: Lixisenatide once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide once daily
Trial: 27222510
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine once daily
Trial: 27222510
Drug: Lixisenatide thrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide thrice daily
Trial: 27222510
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine thrice daily
Trial: 22884766
Drug: Bosutinib 100-600
RxNorm normalized name: bosutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 100-600 mg coadministered with ketoconazole 400 mg
Trial: 22884766
Drug: Bosutinib 600
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 600 mg
Trial: 22884766
Drug: Bosutinib 100-600
RxNorm normalized name: bosutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 100-600 mg
Trial: 20413736
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day (AT‐10)
Trial: 20413736
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/day (AT‐80)
Trial: 20413736
Drug: Cholestyramine 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 8 g/day plus sitosterol 2.5 g/day
Trial: 20413736
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (AT‐10, AT‐80, cholestyramine plus sitosterol)
Trial: 17950677
Drug: AZD0865 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0865 25 mg
Trial: 17950677
Drug: AZD0865 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0865 50 mg